title: Anticoagulant use in real time.
abstract: Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year, VTE affects about 300,000 to 600,000 people in the United States, and death is the first manifestation in one-fourth of this population.(1){Beckman, 2010 #79} Moreover, approximately 10% of the US population has genetic factors that increase their risk for developing thrombosis.(1) In addition to inherited disorders, factors that contribute to VTE include prolonged immobilization, trauma, surgery, cancer, and critically ill patients.(2) Routine assessment and prophylaxis are recommended in these groups to avoid DVT-related complications.(2) Anticoagulants are the mainstay of drugs used in DVT/PE prevention and treatment. Despite the availability of evidence-based guidelines for anticoagulant therapy, there is suboptimal implementation of DVT prophylaxis in hospitalized patients.(3) All anticoagulants are "high-alert" drugs, and judicious use is mandatory to prevent bleeding complications.(4) This review discusses treatment guidelines, monitoring, side effects, and reversal agents available for some anticoagulant drugs approved for VTE. Dissemination of the knowledge via pharmacy education programs significantly improves the adherence to VTE prophylaxis.(5) Understanding the clinical aspects of anticoagulant dispensing as presented in this review is hoped to facilitate implementation of the theoretical knowledge as well as evidence-based guidelines in order to maximize patient benefit.
authors.affiliation: Department of Pharmacy Practice, Texas A&M University, Kingsville, TX, USA.
authors.forename: Divyamani
authors.initials: D
authors.lastname: Srinivasan
authors.forename: Bree
authors.initials: B
authors.lastname: Watzak
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D055118:Medication Adherence; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants